A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
A Multicenter, Prospective, Randomized, Open-label Study to Assess the Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
This was a multinational, multicenter, randomized, open-label study to confirm and expand the efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30 micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for Acute Heart Failure (AHF).
This study was aimed at generating clinical evidence, especially on the short term period (in-hospital and at 30 days) to complement existing and future serelaxin data sets in Acute Heart Failure (AHF).
Inclusion Criteria:
Exclusion Criteria:
Decin II, Czech Republic 405 99, Czechia
Karvina-Raj, Czech Republic 73412, Czechia
Düssledorf, 40217, Germany
Koeln-Nippes, 50733, Germany
Neustadt A.d. Aisch, 91413, Germany
Galdakano, Basque Country 48960, Spain